A tumour-infiltrating lymphocyte therapy of Grit Biotechnology, GT101 is set to enter the Phase II trial by year-end. Credit: CI Photos/Shutterstock.com.

Cell therapy company Grit Biotechnology has secured more than $60m (436.72m yuan) in a Series B funding round to support the development of its pipeline programmes.

China International Capital Corporation led the financing round, which saw investments from Liando Group, Qianhai Ark, Yuanhe Capital and HeFangTian Venture Partnership.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Grit’s existing investors, namely Sherpa Healthcare Partners, Matrix Partners China and Decheng Capital, also took part in the financing round.

Grit plans to utilise the investment proceeds to support the development of its tumour-infiltrating lymphocyte (TIL) pipeline.

These funds will also be used for the Phase II clinical trial of TIL therapy, GT101, and progress next-gen gene-edited TIL products. 

See Also:

GT101 is set to enter the Phase II trial by year-end.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Grit Biotechnology was established in 2019 and is focused on offering transformative therapies for cancer. 

The company uses four technology platforms for developing gene-edited TIL products: StemTexp, StaViral, KOReTIL and genome-wide CRISPR/Cas9 screening platform ImmuT Finder. 

Apart from GT101, the company is developing GT201, a genetically engineered TIL product, and a next-gen TIL product, GT316.  

GT201 has received new drug application clearance from the China Food and Drug Administration and is currently being evaluated in Phase I trials while GT316 is in investigator-initiated trials in the region.

Grit has a 10,000m² GMP-level cell therapy production facility in Suzhou with a workforce of more than 100 specialists.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.